Phaseline

Companies › Guangzhou Gloria Biosciences

Guangzhou Gloria Biosciences: clinical trials, targets and expected readouts

3 active drug programs in 8 registered trials: 3 Phase 1, 2 Phase 3, 2 Phase 2, 1 Phase 4; Oncology, Hematology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Zimberelimab (GLS-010)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Persistent, Recurrent, or Metastatic Cervical Cancer; Solid TumorDec 2026
Motixafortide (BL-8040)
C-X-C chemokine receptor type 4 antagonist
CXCR4Phase 3Multiple Myeloma; Pancreatic Cancer; Acute Myeloid Leukemia; Sickle Cell DiseaseMay 2027
GLS-012–Phase 1Solid TumorDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05909436GLS-012Phase 1Solid TumorOncologyDec 2026
NCT05909436Zimberelimab (GLS-010)Phase 1Solid TumorOncologyDec 2026
NCT07101445Motixafortide (BL-8040)Phase 4Multiple MyelomaOncologyDec 2026
NCT06514508Motixafortide (BL-8040)Phase 3Multiple MyelomaOncologyMay 2027
NCT06442761Motixafortide (BL-8040)Phase 1Sickle Cell DiseaseHematologyJan 2028
NCT04543071Motixafortide (BL-8040)Phase 2Pancreatic CancerOncologyJun 2028
NCT07392970Motixafortide (BL-8040)Phase 2Acute Myeloid LeukemiaOncologyAug 2028
NCT05798819Zimberelimab (GLS-010)Phase 3Persistent, Recurrent, or Metastatic Cervical CancerOncologyDec 2029

Targets

PDCD1 (1) CXCR4 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Companies built like this

Binhui Biopharmaceutical TaiRx Evopoint Biosciences CStone Pharmaceuticals Dizal Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.